Document:

EMPLOYMENT
AGREEMENT BETWEEN

ZANDER
THERAPEUTICS, INC.

AND

David
R. Koos

 

THIS EMPLOYMENT
AGREEMENT (the "Agreement") dated as of June 19, 2018 is entered into between Zander Therapeutics,
Inc., a Nevada corporation, (the "Company") and David R. Koos

("Employee").

 

WITNESSETH:

WHEREAS, Employee
and the Company desire to enter into an agreement providing for the employment by the Company of Employee
upon the terms provided herein.

REPRESENTATIONS AND WARRANTIES

 

A)
Company hereby represents and warrants to Employee as follows;

(i)
Corporate Existence of Company. Company:

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii) No
Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation
or the transactions contemplated hereby and thereby

 

(a)
constitutes or will constitute a violation of the organizational documents of Company,

 

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice
or lapse of time or both, would constitute such a default) under, any indenture, mortgage,
deed of Company, loan agreement, lease or other agreement or instrument to which Company is a
party or by which Company or any of its properties may be bound,

 

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court
or Governmental Authority directed to Company or any of its properties in a proceeding to which
its property is or was a party.

 

(B)
Employee hereby represents and warrant to Company as follows:

(i)
No Conflicts. None of the execution, delivery and performance of this Agreement by Employee, or the consummation of the transactions
contemplated hereby and thereby

(a)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Trust, loan agreement, lease or other agreement or instrument
to which Employee is a party or by which Employee or any of its properties may be bound,

(b)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Employee or any of their properties in a proceeding to which its property is or was a party.

    	 	1	 

     

    

 

AGREEMENT:

NOW,
THEREFORE, in consideration of the foregoing and the mutual promises and agreements set forth herein, the parties hereto, intending
to be legally bound, hereby agree as follows:

1.
Employment. During the Employment Period (as defined in Section 2), the Company hereby employs Employee and Employee hereby accepts
employment.

2.
Term. The Term of this Agreement shall commence on June 14, 2018 and shall expire on August 14, 2020 unless sooner terminated
in accordance with the provisions of Section 6 hereof; provided, however, that the term of this Agreement may be extended by mutual
agreement. The period from the commencement of the term of this Agreement to the date of its expiration or sooner termination
shall be considered to be the “Employment Period" hereunder. AT THE END OF THE EMPLOYMENT PERIOD, THIS AGREEMENT MAY
BE EXTENDED FOR AN ADDITIONAL YEAR BY WRITTEN MUTUAL CONSENT OF THE PARTIES HERETO.

3.
Duties. Employee shall be granted the title of Chief Executive Officer of the Company subject to the authority of the Company's
Board of Directors (the “BoD”). Employee shall perform such duties commensurate with his office and as directed the
BoD such duties to include, but not be limited to:

 

See
Schedule 1.

 

During
the Employment Period, Employee shall perform his duties hereunder in a diligent manner, subject to the provisions of Schedule
1 of this Agreement; devoting such amount of his business time, attention and efforts to the affairs of the Company within the
scope of his employment as is necessary for the proper rendition of such service and shall use his best efforts to promote the
best interests of the Company. Employee's services shall be rendered when and as required by the Board and in accordance with
the BoD's instructions, direction and control.

It
is agreed that Employee will only devote such time as to effectively conduct duties and responsibilities associated with this
position pursuant to this Agreement.

4.
Compensation Salary. During the Employment Period, Company shall pay Employee salary at the rate of:

 

	 	(i)	During
    the period commencing June 14, 2018 and ending upon the expiration of the Employment Period, Company shall pay Employee salary
    at the rate of $16,667 per month prorated for any partial employment month ("Salary"). Salary shall be paid on a
    monthly basis (“Payday”). In the event that Payday falls on a Saturday, Sunday or holiday, Salary shall be paid
    on the next business day. 

 

 

The
Company acknowledges employee has been serving without an employment agreement. In order to compensate the employee for work previously
performed, employee shall received an employment agreement signing bonus of 800 Series AA Preferred shares and 150,000 Series
M Preferred shares of the Company's stock.

 

    	 	2	 

     

    

5.
Benefits.

a.
During the Employment Period, Employee shall be entitled to participation in any profit sharing plan, retirement plan, group life
insurance plan or other insurance plan, medical expense plan, medical and dental insurance and other benefit arrangements maintained
by the Company for its employees generally and, if applicable, their family members. In addition, Employee shall be entitled to
15 days paid vacation (“Vacation”) subject to having given fourteen days prior notice to the Company of Employee’s
intent to Vacation.

b.
Stock Compensation.  Employee acknowledges he has received 500,000 Series M Preferred shares that are fully vested and considered
compensation in full for service prior to the execution of this agreement .Employee acknowledges that any Series M Shares 
issued prior to or pursuant to this Agreement will not be  registered pursuant to the Securities Act of 1933 , shall constitute
“restricted securities” as that term is defined in Rule 144 promulgated under the Securities Act of 1933 and shall
contain the following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

d. Milestone
Shares. In the event the Company's Chief Scientific Officer and / or Chief Financial Officer achieve success so as to trigger
their milestone share awards, the Employee shall receive a milestone share award equal to any awards attained by the Chief Scientific
Officer and / or the Chief Financial Officer, with a total of 10,000,000 newly issued Series M Preferred shares of the Company
stock (fully vested as they are awarded).

6.
Termination.

a.
Employee's employment hereunder shall terminate upon the earlier of:

(i)
the expiration of the Employment Period,

(ii)
the death of Employee,

(iii)
the expiration of a continuous period of thirty (30) calendar days during which Employee is unable to perform his material duties
due to physical or mental incapacity,

(iv)
termination by the Company due to “just cause,”

(v)
termination by Employee due to a material breach of this Agreement by the Company. The exercise of the right of the Company or
Employee to terminate this Agreement pursuant to clauses (iv) or (v) hereof, as the case may be, shall not abrogate the rights
and remedies of the terminating party in respect of the breach giving rise to such termination.

    	 	3	 

     

    

 

b.
"Just cause" hereunder shall be defined and limited to mean:

(i)
Employee's failure or refusal, as determined by the BoD in its discretion, to perform specific directives which are consistent
with the scope and nature of Employee's duties and responsibilities as set forth herein (including the duties described in Section
3), which failure or refusal continues after notice thereof and a reasonable time to cure; such reasonable time to be determined
by the BoD.

(ii)
Employee's conviction for a felony or any crime involving moral turpitude, fraud, or misrepresentation, or the presentation of
proof satisfactory to the BoD in the exercise of its reasonable judgment of Employee's misappropriation or embezzlement of funds
or assets from the Company;

(iii)
any intentional act having the purpose and effect of injuring the reputation, business or business relationships of the Company
in any material respect; and

(iv)
any breach by Employee of any material provision of this Agreement, including, without limitation, the restrictive covenants contained
in Section 7 hereof.

c.
In the event of any dispute regarding the existence of Employee's incapacity hereunder, the matter wil1 be resolved by the determination
of a physician qualified to practice medicine in California selected by the BoD. For this purpose, Employee will submit to appropriate
medical examinations.

d.
If Employee's employment hereunder is terminated pursuant to Section 6 the Company shall have still owe compensation to the Employee
until this agreement has reached completion of its term (June 14, 2020) except the Company shall have no further obligations or
liabilities hereunder in the event Employee is terminated due to Employee's conviction for a felony or any crime involving embezzlement,
moral turpitude, fraud, or misrepresentation.

7. Restrictive
Covenant.

a.
Non-disclosure. Employee has, and during the Employment Period will have, access to confidential information and trade secrets
of the Company and its subsidiaries (the "Confidential Information") that may include, among other things:

(i)
Financial information

(ii)
Supply and services information

(iii)
Marketing information

(iv)
Personnel information

(v)
Customer information

(vi)
Product information

(vii)
The Company’s procedures, systems, policies and processes of operation.

Employee
shall at all times during his employment by the Company and thereafter hold in strictest confidence any and all Confidential Information
that may have come or may come into Employee's possession or within Employee's knowledge. Employee agrees that neither he nor
any person or entity, directly or indirectly, controlled by or under common control with the Employee (an "Affiliate")
will for any reason, except in the course of performing his duties hereunder, for himself or any other person, use or disclose
to anyone, exclusive of Company employees, agents, representatives, or independent consultants to the Company or any of its subsidiaries
or Affiliates of the Company, any Confidential Information; provided, however, that Employee may disclose Confidential Information
which (i) has become generally available to the public other than as a result of a breach of this Agreement by Employee or (ii)
Employee is compelled to disclose pursuant to subpoena or an order by a court competent jurisdiction; provided that, if Employee
is so required to disclose any Confidential Information pursuant to the foregoing clause (ii), Employee shall provide advance
written notice to the Company, to the extent possible, to allow the Company to seek an appropriate protective order therefore
(iii) Potential advisors, employees, or investors of the Company where there is a reasonable expectation of confidentiality. All
Confidential Information shall remain the Company's property and shall be returned (or, at the Company's option, destroyed) upon
the Company's written request.

    	 	4	 

     

    

 

b.
Non-Solicitation of Employees. Employee agrees that from the date hereof and continuing for a period of three years following
the termination of this Agreement for whatever reason (the "Non-Compete Period"), neither Employee nor any Affiliate
of Employee will solicit or hire for employment any officer, director or employee of the Company who was employed by the Company
at any time within twelve months prior to the act of solicitation.

c.
Non-Competition. Employee agrees that, other than with the approval of the CEO, which approval shall not be unreasonably withheld,
during the Employment Period, neither Employee nor any Affiliate of Employee will, directly or indirectly, become a shareholder,
director, officer, agent, partner or employee of, or otherwise hold any ownership interest in, any person, firm or entity engaged
in any Competitive Business (as defined below), engage as a sole proprietor in any Competitive Business, act as a consultant to
or assist any of the foregoing or otherwise engage or participate in any Competitive Business; provided, however, that the foregoing
shall not prohibit the ownership by Employee of less than ten percent (10%) of the outstanding shares of the stock of any corporation
engaged in any Competitive Business, which shares are regularly traded on a national securities exchange or in any over-the-counter
market. For the purpose hereof, "Competitive Business" means the ownership, operation, development, marketing of the
services related to, or management of cellular therapeutics within the United States.

d.
Consideration, Relief, Reformation; Severability. The Company has specifically bargained for the covenants set forth in this Section
6 in consideration for the compensation, experience, and information that Employee will gain or receive in connection with his
employment by the Company. Employee agrees that the covenants set forth herein will not preclude Employee from engaging in any
lawful profession, trade or business or from being gainfully employed necessary to provide Employee, his family members and dependents
a standard of living to which he and they have been accustomed and may expect. Employee acknowledges and agrees that the restrictive
covenants in this Section 6 have been specifically negotiated, are reasonable in all respects, including, without limitation,
their geographic scope and duration, and may be enforced by specific performance or otherwise. Employee shall not raise any issue
of reasonableness as a defense in any proceeding to enforce any of such covenants. Notwithstanding the foregoing, in the event
that a covenant included in this Agreement shall be deemed by any court to be unreasonably broad in any respect, it shall be modified
or limited in its geographic scope, duration or otherwise to the extent necessary to make it reasonable while preserving its restrictive
nature to the maximum degree possible and shall be enforced accordingly; provided however, that if, notwithstanding the foregoing,
a court of competent jurisdiction shall hold any of the covenants contained in Sections 7 (a), (b) or (c) to be unenforceable
(as so modified), then the unenforceable covenant shall be deemed eliminated from the provisions of this Agreement for the purpose
of those proceedings to the extent necessary to permit the remaining covenants to be enforced so that the validity, legality or
enforceability of the remaining provisions of this Agreement shall not be affected thereby.

8.
Developments.

Employee
hereby assigns to the Company his entire right, title and interest in all know how, discoveries and improvements,
customer lists, trade secrets and ideas, writings and copyrightable material, which may be conceived by Employee
or developed or acquired by him during the term of this Agreement, which may pertain directly to the Company's business
and were developed with Company resources. Employee agrees to promptly and fully disclose in writing all such developments. Employee
will, upon the Company's request, execute, acknowledge and deliver to the Company all instruments
and do all other acts which are necessary or desirable to entitle the Company to all rights in the foregoing
and enable the Company to file and prosecute applications for, and to acquire, maintain and enforce all letters, trademark
registrations or copyrights with respect to the foregoing in all countries.

    	 	5	 

     

    

 

9.
Remedies.

Employee
acknowledges that any material breach of this Agreement will cause irreparable harm to the Company, that such harm will be difficult
if not impossible to ascertain, and that the Company shall be entitled to equitable relief, including injunction, against
any actual or threatened breach hereof, without bond and without liability should such relief be denied, modified or vacated.
Neither the right to obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the
Company from any other remedy.

10.
Legal Counsel.

Employee
acknowledges that Employee has carefully read this Agreement and understands all of the terms hereof and that Employee
has been given the opportunity to discuss this Agreement with Employee's private legal counsel and
has availed himself of that opportunity to the extent Employee wishes to do so.

11. Notices.

All
notices, requests and other communications under this Agreement shall be in writing and shall be deemed to have been received
five business days after having been deposited in the United States Mail and enclosed in a registered or certified post-paid
envelope; one day after having been sent by overnight courier on a business day or otherwise at the open of
business on the next succeeding business day; when personally delivered or sent by facsimile communications equipment
of the sending party on a business day or otherwise at the open of business on the next succeeding business day; and, in
each case, addressed to the respective parties at the addresses stated below or to such other changed addresses
that the parties may have fixed by notice in accordance herewith.

If
to the Company:

Zander
Therapeutics, Inc.

4700
Sprint Street, Suite 304

La
Mesa, CA 91942

 

Attn:
David Koos, CEO

 

 If
to Employee:

David
Koos

c/o
Zander Therapeutics, Inc.

4700
Sprint Street, Suite 304

La
Mesa, CA 91942

venturebridge@gmail.com

 

12.
Waiver of Breach.

A
waiver by the Company or Employee of a breach of any provision of this Agreement by the other party shall
not operate or be construed as a waiver of any subsequent breach by the other party.

 

    	 	6	 

     

    

 

13. Entire
Agreement.

This
instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes any
prior agreements of the parties with respect to the subject matter hereof. It may be changed only
by an agreement in writing signed by a party against whom enforcement of any waiver, change,
modification, extension or discharge is sought.

 14.
Applicable Law.

 The
terms and conditions of this Agreement shall be governed by and construed in accordance with the laws of the State or
California. Any action to enforce this Agreement shall be brought in the state courts located in San Diego County, State
of California.

IN
WHITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

	By:	 	 
	 	 	 
	/s/
    David Koos	 	 
	David Koos	 	 
	Chief Executive Officer	 	 
	 	 	 
	 	 	 
	By:	 	 
	 	 	 
	/s/
    David Koos	 	 
	David R. Koos, employee	 	 

 

    	 	7	 

     

    

Schedule
1.

 Employer:
Zander Therapeutics, Inc.

 Location:
Company Headquarters and any remote offices

 

Description:

 

Job
Description – Chief Executive Officer

 

Job
Summary

 

The CEO's leadership
role entails being ultimately responsible for all day-to-day management decisions and for implementing the Company's long
and short term plans. The CEO acts as a direct liaison between the Company's Board of Directors and management of the Company
and communicates to the Board on behalf of management.

The
CEO supervises and controls all strategic and business aspects of the company. As CEO, you will be the first in command in
the company and responsible for giving the proper strategic direction as well as creating a vision for success.

Responsibilities

	 	•	Develop
    high quality business strategies and plans ensuring their alignment with short-term and long-term objectives

 

	 	•	Lead
    and motivate subordinates to advance employee engagement develop a high performing managerial team

 

	 	•	Oversee
    all operations and business activities to ensure they produce the desired results and are consistent with the overall strategy
    and mission

 

	 	•	Make
    high-quality investing decisions to advance the business and increase profits

 

	 	•	Enforce
    adherence to legal guidelines and in-house policies to maintain the company’s legality and business ethics

 

	 	•	Review
    financial and non-financial reports to devise solutions or improvements

 

	 	•	Build
    trust relations with key partners and stakeholders and act as a point of contact for important shareholders

 

	 	•	Analyze
    problematic situations and occurrences and provide solutions to ensure company survival and growth

 

	 	•	Maintain
    a deep knowledge of the markets and industry of the company

 

    	 	8SECURITIES
PURCHASE AGREEMENT

ZANDER
THERAPEUTICS, INC.

 

THIS
SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the "Company") whose address is 4700 Spring Street, St 304, La MeCalifornia 91942, and Herrick Family Trust ("Purchaser"),
a person whose address is (5022 Royal Vista Court, Westlake Village, CA 91362)

 

WHEREAS:

 

The
Purchaser desires to purchase shares of the common stock of the Company ("Shares") in accordance with the terms and
conditions set forth herein. 

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

 

 1. Purchase Price

The
purchase price per Share ('"Purchase Price"), payable in US Dollars, shall be $1.00 per Share. 

 2. Form of Payment

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company.

WIRE
INSTRUCTIONS:

 

Zander
Therapeutics Wire Instructions: 

    	 	1	 

     

    

 

Issuance of Stock 

10
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

 3. Purchaser's Representations and Warranties

 

(a)  
As of the date hereof, the Purchaser is purchasing
the Shares for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to
sales registered or exempted from registration under the Securities Act of 1933, as amended (the "Act").

 (b) The Purchaser is an '"accredited investor" as that term is defined in Rule 501(a) of Regulation D promulgated under the Act.

(c)  
The Purchaser and its advisors if any, have been,
furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer
and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company
has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information
is disclosed to the public prior to such disclosure to the Purchaser.

 (d) Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(e)  
The execution, delivery and performance of this
Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or regulation or ordinance of any governmental
authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of
any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser
is or may be bound.

 4. Company's representations and warranties

(a) Company
is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has
the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the
consent, approval or

    	 	2	 

     

    

authorization of, or obligation to notify, any person, entity or governmental agency which consent has
not been obtained.

(b) 
The execution, delivery and performance of this
Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any governmental
authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of
any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which Company is
or may be bound.

 5. Restricted Securities Acknowledgement

SHARES
TO BE ISSUED PURSUANT TO THIS AGREEMENT WILL NOT BE REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE
SECURITIES ACT OF 1933 OR THE SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION. 

Purchaser
acknowledges that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933
and shall constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Act, and shall
contain the following restrictive legend:

"THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ''ACT"), OR SECURITIES LAWS OF ANY
STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."

 9. Entire Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 10. Governing Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in

    	 	3	 

     

    

 

California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions
of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorneys'
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

 

IN
WITNESS WHEREOF, the parties have hereunto executed
this Agreement on the 27th day of August, 2018.

 

 

Zander
Therapeutics, Inc.

/s/David
Koos

Its:
CEO

August
27, 2018

 

Purchaser

/s/Joseph
Anthony Herrick

By:
Joseph Anthony Herrick for Herrick Family Trust

August
27, 2018

    	 	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]